medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

TITLE PAGE

Effects of oral anticoagulant adherence on stroke, death, and major bleeding in patients with atrial fibrillation: A long-term retrospective cohort study

Abdollah Safari, PhD[a], Hamed Helisaz, PhD[b,c], Shahrzad Salmasi, PhD[d], Adenike Adelakun, MSc[e], Mary A. De Vera, PhD[e,f], Jason G. Andrade, MD[g,h,i,k], Marc W. Deyell, MD MSc[g,i,j], Peter Loewen, PharmD[e,f,i]

[a] School of Mathematics, Statistics, and Computer Science, College of Science, University of Tehran, Iran

[b] Faculty of Applied Science, University of British Columbia

[c] GranTAZ Consulting Ltd., Vancouver, Canada

[d] McGill University, Montreal, Canada

[e] Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

[f] Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada

[g] Division of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, Canada

[h] Atrial Fibrillation Clinic, Vancouver General Hospital, Canada

[i] UBC Center for Cardiovascular Innovation, Vancouver, Canada

[j] Centre for Health Evaluation & Outcome Sciences, Providence Health Care Research Institute, Canada

[k] Montreal Heart Institute, Université de Montréal, Montréal, Canada

Body word count: 3499

Funding: This research was supported by Canadian Institutes of Health Research grant (FRN 168896). Dr. Loewen's research is also partially supported by the UBC David H MacDonald Professorship in Clinical Pharmacy (Vancouver, Canada). Dr. Salmasi's research was supported by a Canadian Institutes of Health Research Postdoctoral Fellowship award.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Disclosure: Dr. Andrade has received honoraria from Bayer, Biosense-Webster, BMS Pfizer, Medtronic, and Servier, as well as Grants from Medtronic. Dr. Deyell has received honoraria from Pfizer, Servier, and Bayer. Other authors have no conflicts of interest to disclose.

Disclaimer: Access to data provided by the Data Steward(s) is subject to approval, but can be requested for research projects through the Data Steward(s) or their designated service providers. All inferences, opinions, and conclusions drawn in this publication are those of the author(s), and do not reflect the opinions or policies of the Data Steward(s).

Address for correspondence:

Peter Loewen B.Sc.(Pharm), ACPR, Pharm.D., FCSHP, R.Ph.
Associate Professor | Faculty of Pharmaceutical Sciences
David H MacDonald Professor in Clinical Pharmacy
Faculty, UBC Collaboration for Outcomes Research & Evaluation
Researcher, UBC Center for Cardiovascular Innovation
The University of British Columbia | Vancouver Campus
2405 Wesbrook Mall | Vancouver, BC Canada V6T 1Z3
phone 604 506 8011 | peter.loewen@ubc.ca

Acknowledgements: The authors are grateful to Dr. Anita I. Kapanen from University of British Columbia for her expert support of the data stewardship and ethical oversight of this study.

Disclaimer: All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not reflect the opinions or policies of the Data Steward(s).

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

ABSTRACT

Background

Patients with atrial fibrillation (AF) are frequently nonadherent to oral anticoagulants (OACs) prescribed for prevention of stroke and systemic embolism (SSE). The effects of OAC adherence on clinical outcomes are uncertain because previous studies used short time periods, treated adherence as binary, and/or excluded VKA users. Our objectives were to quantify the relationship between adherence to OACs as a continuous variable and AF-related clinical outcomes, and to compare the consequences of nonadherence between OAC classes and individual OACs.

Methods

This retrospective, observational cohort study included incident cases of AF from population-based administrative data of 5 million British Columbians from 1996 to 2020. The exposure of interest was proportion of days covered (PDC) for incident OAC prescriptions during 90 days before a clinical event or end of follow-up. Multivariable Cox proportional hazard models were used to evaluate time to first composite outcome of SSE, transient ischemic attack (TIA), or death and SSE and several secondary outcomes. Models were also stratified by the OAC patients were receiving within 90 days of the outcome event.

Results

The study cohort included 34,946 patients (mean age 70.1, 45% female) with median follow-up of 6.7 years. Each 10% absolute decrease in PDC was associated with a 4.3% (95%CI 2.9-5.6) and 10.3% (95%CI 7.5-13.0) increase in hazard of SSE, TIA, or death for VKA and direct OAC (DOAC) users, respectively. For SSE, hazard increases per 10% PDC reduction were 22.5% (95%CI 19.6-25.4) and 34.2% (95%CI 28.2-40.6) for VKA and DOAC, respectively. Similar significant effects were seen for all secondary efficacy outcomes. Differences between VKA and DOAC were statistically significant for all outcomes ($p<0.001$ all contrast tests) except major bleeding.

Conclusions

Even small reductions in OAC adherence in patients with AF are associated with significant increases in risk of SSE and death, and these effects are significantly greater with DOAC nonadherence than with VKA nonadherence. These results suggest that DOAC recipients are more vulnerable than VKA recipients to increased risk of stroke and death even with small reductions in adherence. The worsening efficacy outcomes associated with decreasing adherence occur without any benefit in terms of major bleeding reduction.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

INTRODUCTION

Atrial fibrillation (AF) is the most common chronic arrhythmia, affecting 3% of the world's population.[1, 2] Stroke prevention is a cornerstone of AF management because patients with AF are at 5 times higher risk of experiencing a stroke than those without AF, and strokes secondary to AF are more debilitating and more lethal than those due to cerebrovascular disease.[3, 4] Oral anticoagulants [OACs; vitamin K antagonists (VKAs, typically warfarin), Direct Oral Anticoagulants (DOACs; apixaban, dabigatran, edoxaban and rivaroxaban)] are highly effective for stroke prevention.[5-8] Unfortunately, it is estimated that 33-50% of patients are nonadherent to their OACs and miss, on average, 30% of their OAC doses.[9, 10]

It is important to quantify the relationship between OAC adherence and clinical outcomes in patients with AF because the clinical consequences of nonadherence are potentially devastating and costly. The few existing studies have treated adherence as a binary exposure (e.g. ≥ 80 or < 80%) and evaluated the effect of adherence over only short follow-up durations (< 2 years),[11-16] despite OAC therapy being lifelong and adherence being a continuous spectrum known to vary over time.[17] Existing studies have typically excluded VKA users because of difficulties in measuring adherence due to its variable dosing regimens. It is conceivable that patients with different levels of adherence who would otherwise be simply categorized as nonadherent experience different clinical event rates, and that nonadherence to VKA vs. DOACs has significantly different clinical consequences due to their different pharmacodynamics.[18-20] Hence, significant uncertainty remains about the relationship between OAC adherence and the risk of stroke or systemic embolism (SSE) and death.

Given our limited understanding of the multidimensional nature of medication adherence, reliable interventions to improve adherence in patients with AF remain elusive.[9, 21] A more comprehensive understanding of these phenomena could help identify patients with adherence problems who are most at risk of adverse clinical outcomes and could inform the design of adherence interventions to maximize their impact on stroke and death.

To address these knowledge gaps, our objectives were to quantify the relationship between adherence to OACs and various AF-related clinical outcomes, and to compare the consequences of nonadherence to VKA to DOAC in terms of these outcomes.

METHODS

Study design and setting

This was a retrospective observational cohort study using de-identified patient records from administrative data (Population Data BC[22]) for the entire population of the province of British Columbia (BC), Canada (~5 million residents). This included the following databases: Medical Services Plan (MSP)[23] billing for outpatient visits, Discharge Abstract Database (DAD)[24] containing extensive data from hospitalizations, the Consolidation File[25] containing demographics such as sex, place of residence, and registration with the provincial healthcare

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

plan, and the Vital Statistics Database[26] containing date and primary cause of death. Data for all prescription medications dispensed outside of hospital between January 1996 and December 2019 was retrieved from the PharmaNet database and linked to the other datasets.[27] Person-level linkage used a study-specific unique identifier created by the data provider and linkage was performed before the data was released to the investigators.

The study was approved by the University of British Columbia Clinical Research Ethics Board (H17-02420). Study reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE) extension guides.[28-30]

Participants

We created an incident cohort of adult patients ≥ 18 years old with non-valvular AF. Using the algorithm validated by Navar et al. with a positive predictive value of 95.7%,[31] we included individuals who had ≥3 recorded visits in MSP or DAD[23,24] related to AF or atrial flutter, with at least one of the three recorded visits being AF-specific (ICD-9 = 427.31; ICD-10 = I48; Supplemental Appendix A). To distinguish AF for which anticoagulation therapy is normally considered from potentially transient/reversible AF, at least two of the visits had to occur within one year.[32]

Next, using Anatomical Therapeutic Chemical (ATC) codes from PharmaNet[27] records, we captured all dispensed prescriptions for OACs available in the study jurisdiction (warfarin, dabigatran, apixaban, rivaroxaban, edoxaban). Individuals were excluded if they did not have continuous public medical insurance coverage during the 1-year prior to their first OAC prescription fill, or if their first OAC prescription occurred before 1997 to permit 1-year baseline covariate ascertainment, or after Jan 2019 to ensure ≥1 year follow-up before end of the data.

The date on which the first OAC prescription was filled after the first AF diagnostic code (or within 60 days before the first AF code), was referred to as the "index date" (Figure 1). Baseline patient characteristics were measured during 12 months prior to the index date, referred to as the "baseline period". Follow-up ended at the time of first study event or on the date of the last available data, whichever came first.

To ensure we included only incident AF cases and incident OAC use, those with an AF code or OAC prescription fill during the 3 years prior to their AF diagnosis date or their index date, respectively, were excluded. To improve specificity, we excluded individuals with indications for OAC other than non-valvular AF (e.g., venous thromboembolism, rheumatic valve disease; Supplemental Appendix A) based on codes appearing any time before their index date. We also excluded patients with two different OACs filled on the same index date. Finally, because ≥2 OAC prescription fills were required to measure adherence, patients with only one OAC prescription fill were excluded.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Patients were followed from the index date until the end of their follow-up time, defined as December 2019, date of death, or discontinuation of their public medical insurance enrolment, whichever came first.

Variables

The primary exposure of interest was OAC adherence, measured as proportion of days covered (PDC).[33-35] Ninety-day consecutive windows (the typical length of dispensed prescriptions in PharmaNet[27]) were created for each patient between their first OAC prescription fill date and the end of their follow-up and PDC was calculated for each window.[36] If a patient permanently discontinued their medication, all windows after their last supply ran out were assigned a PDC of zero until the end of their follow-up period. To address variable dosing of warfarin based on international normalized ratio (INR) results, we used the validated Random Effects Warfarin Days' Supply (REWarDS) method to estimate the average daily dose for warfarin in the computation of PDC for warfarin.[37] PDC was multiplied by 10 (representing PDC deciles) to allow more meaningful interpretation of its impact on risk of outcomes in our study models. The co-primary outcomes were SSE and the composite of SSE, transient ischemic attack (TIA), or death. Secondary outcomes were all-cause death, cardiovascular death, SSE or TIA, ischemic stroke, hemorrhagic stroke, major bleeding, and nontraumatic intracranial hemorrhage. All outcomes were measured as time to first event.

All outcomes except death were based on the first or second most responsible causes of hospitalization as recorded in DAD.[24] Death and its cause were ascertained from the Vital Statistics registry.[26] The primary outcome of SSE was chosen to align the Canadian Cardiovascular Society's AF surveillance quality indicators program primary outcome and used the same validated ascertainment scheme.[38, 39] The other primary outcome was chosen to avoid competing risk between SSE and death and included TIA using a validated ascertainment scheme to encompass all stroke-related outcomes.[40]

Covariates included in study analyses were age, sex, SSE risk score, CHA_2DS_2-VASc (Congestive heart failure, Hypertension, Age ≥75, Diabetes, prior Stroke or systemic embolism, Vascular disease, Age 65-74, Sex [female]),[41] major bleeding risk score, modified HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile INR, Elderly, and Drugs/alcohol),[42, 43] comorbidities (individual components of CHA_2DS_2-VASc and HAS-BLED scores), socioeconomic status, neighbourhood income quintile, number of medical services plan billings, number of hospitalizations, time from AF diagnosis to OAC start, Charlson comorbidity index (CCI),[44] and polypharmacy (5 or more concurrent medications, not including OAC).[45] Following convention, CHA_2DS_2-VASc and HAS-BLED scores were binarized at ≥2. Due to their highly skewed distributions, number of hospitalizations during follow-up was grouped into four categories: 0, 1, 2, and ≥3 admissions, and time to OAC initiation was grouped into three categories: <3 months, 3 to 9 months, and >9 months. Multivariable imputation was used to impute missing values for SES (the only covariate with missing values).

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

To enable analyses of association between specific OAC drugs and the study outcomes, we created an additional variable for OAC at time of the event using a novel scheme described in Supplemental Appendix A4. For our main exposure of interest, PDC, to study the effect of OAC adherence and OAC drug class separately, we included their corresponding information in three separate variables: PDC, OAC drug class, and individual OAC drug. The former measured patients' adherence to any prescribed OAC medication calculated during 90-day window prior to the event date or end of follow-up, and the others captured the class or drug temporally associated with the event.

To avoid collinearity, we selectively included HAS-BLED, CHA_2DS_2-VASc, and CCI scores in our study models based on their relevance. We used CHA_2DS_2-VASc score for stroke or death outcomes and HAS-BLED score for bleeding outcomes. CCI was not included in any models due to its high correlation with both scores.

Statistical analyses

To evaluate the association between OAC adherence and time to clinical outcomes, multivariable Cox proportional hazard models were constructed that incorporated PDC and the study covariates. To ensure clinical events were first occurrences, for models including stroke (any type) or major bleeding, we excluded patients who had that event in the previous 5 years. For each model, history of other study outcomes within the previous year was also included as a covariate. For example, when stroke was among the model outcomes, history of major bleeding was used as a covariate in the model, and vice-versa. For outcomes involving death, history of stroke and major bleeding were both included in the model. For all analyses we used each patient's OAC PDC during the 90-days prior to the event or end of follow-up, whichever came first. Sex was included as a covariate in all models regardless of its contribution and we constructed separate Cox models for females and males for the primary outcomes.

For our second objective, we hypothesized that the relationships between PDC and time to clinical outcomes would vary significantly based on the OAC class (VKA or DOAC) and/or OAC drug the patient was receiving at the time of their event.[46, 47] We evaluated this in the initial Cox models by examining the significance of the PDC covariate hazard ratio (HR) regardless of patients' OAC drug class. Then, to allow the effect of PDC on the hazard of outcomes to be different for patients under different OAC drug classes at event time, we fitted the Cox models with an additional PDC:OAC class interaction term. We also did contrast analyses comparing the PDC HRs between VKA and DOAC recipients. Cox models with adherence to individual OAC drugs as covariates were constructed for the primary outcomes using similar methods.

Model results are presented with hazard ratios (HR) and 95% confidence intervals (95%CI) for covariates. HRs of PDCs are changes in risk of outcome per 10% absolute increase in PDC. For ease of interpretation, associations between PDC and study outcomes are also presented as percent increase in hazard of outcome per 10% absolute decrease in PDC.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Sensitivity analyses

To identify period effects, we fitted the models on patients diagnosed after 2010 when both OAC drug classes were available. To evaluate the scheme used to assign patients an OAC drug class at event time, similar Cox models were fitted on only patients with a stable OAC (no recent drug switches or stopped medications), and different gap times (5, 7, or 10 days) prior to event date were used in the scheme to test their effects on classification and outcomes. To study the effect of PDC on outcomes among only patients with an active OAC, we used similar Cox models but excluded patients with no OAC at event date. Further sensitivity analyses were conducted to test the robustness of the results against different pre-event PDC periods: 30 days and 180 days vs. conventional 90-day windows. We evaluated the effects of excluding people with a prior similar event by running the models without that exclusion criterion. Finally, to identify residual confounding due to healthy adherer effects,[48, 49] we performed analyses using accidental death as the falsification endpoint.[50]

All analysis was conducted using R v4.0.5 (R Core Team, Vienna, Austria, 2021) and RStudio v1.3.1039 (RStudio Team, Boston, US, 2020).

RESULTS

Participants

The cohort included 34,946 people; 44.5% were female, and average age was 70.1 (11.3). Median follow-up time was 6.7 years (interquartile range (IQR): 4.0, 10.7). The median number of OAC prescriptions filled during follow-up was 42 (IQR 20, 66) per patient. Other characteristics of the included patients are shown in Table 1.

During follow up 14,136 SSE, TIA, or death events and 1928 SSE events occurred. Table 2 shows the number of events included and median time to event in each study model.

Effects of OAC adherence on clinical outcomes

Results of the time-to-event analyses of the effect of PDC on outcomes are shown in Table 3 and Figure 2. Primary outcomes were modelled with and without the PDC:OAC drug class interaction term and secondary outcomes were modeled only with the interaction term. Figure 3 illustrates the relationship between log relative hazard of the primary outcomes and PDC by OAC class from the Cox regression models. The figure shows the stronger relationship between PDC and the primary outcomes among DOAC recipients versus VKA recipients (steeper orange lines), and the gap between orange and blue lines reflects more patients with higher risk of outcomes were prescribed VKA versus DOAC.

There were too few events to model outcomes for nontraumatic ICH (179 events), and death due to bleeding (305 events), AF (603 events), or stroke (803 events).

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Individual OAC analyses

Effects of adherence to individual OACs on the primary outcomes are shown in Figure 4. Too few participants were receiving edoxaban to include it in the models. Contrast testing revealed significant differences in hazards for all three DOACs compared to VKA, except dabigatran vs. VKA for SSE.

Sex-based analyses

Sex-specific Cox models showed that for females, a 10% absolute decrease in PDC for VKA was associated with a 4.5% increase in hazard of SSE, TIA, or death (HR 0.957; 95%CI 0.939 – 0.977), and 10.3% increase in hazard for DOAC recipients (HR 0.907; 95%CI 0.873 – 0.943). The corresponding models for males showed a 10% absolute decrease in PDC for VKA was associated with a 4.2% increase in hazard of SSE, TIA, or death (HR 0.960; 95%CI 0.943 – 0.978), and 10.5% increase in hazard for DOAC recipients (HR 0.904; 95%CI 0.874 – 0.934). Contrast between VKA and DOAC was significant in both sets of sex-specific models ($p<0.017$). For SSE, in the females-only Cox model, a 10% absolute decrease in PDC for VKA was associated with a 21.7% increase in hazard of SSE (HR 0.822; 95%CI 0.794 – 0.850), and 32.1% increase in hazard for DOAC recipients (HR 0.757; 95%CI 0.705 – 0.812). The corresponding models for males showed a 10% absolute increase in PDC for VKA was associated with a 24.2% increase in hazard of SSE (HR 0.805; 95%CI 0.778 – 0.833), and 36.2% increase in hazard for DOAC recipients (HR 0.734; 95%CI 0.690 – 0.780). Contrast between VKA and DOAC was significant in both sets of sex-specific models ($p<0.039$).

Sensitivity analyses

Confining the primary analyses to patients who initiated OAC therapy after 2010, when at least one alternative to VKA was available, had no significant effect on the model outputs. Choosing a longer window of PDC prior to events (180 days) resulted in more model instability and sharply reduced effect sizes, indicating clinical events are closely related to short-term OAC-taking behaviours rather than long-term preventive effects, as hypothesized. Sensitivity analysis of the robustness of our scheme to attribute drug classes to clinical events showed that different cut-offs for number of days prior to events for drug changes (5d, 7d, 10d) did not affect the classification proportions. Exclusion of patients with a prior similar event from study models had negligible effects on the results (Supplemental Appendix A6.3, A6.4). The falsification analyses using accidental death as an outcome showed no association with PDC, confirming healthy adherer effects did not contribute significantly to our results.

DISCUSSION

In this large population-based cohort study of incident AF patients with incident OAC use, we found strong associations between OAC adherence and major clinical outcomes. These associations were markedly different between the OAC drug classes patients were prescribed at the time of their event. For the primary outcomes, adherence to DOAC was significantly more

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

strongly associated with events than adherence to VKA, after adjustment for available confounders. For DOACs, each 10% absolute decrease in adherence was associated with a 34.2% increase in risk of SSE and 10.3% increase in risk of SSE, TIA, or death. For VKA the corresponding increased risks were 22.5% and 4.3%, respectively. Similar statistically significant relationships were seen with secondary outcomes of SSE or TIA and ischemic stroke. These effects were similar in magnitude among individual DOACs (dabigatran, apixaban, and rivaroxaban). Strikingly, there was a strong association between DOAC adherence and all-cause and cardiovascular death, which was not seen for VKA use.

These results confirm the importance of achieving maximal adherence in OAC recipients with AF, but especially among DOAC recipients given the much sharper declines in efficacy we observed for nonadherence to DOACs than for VKA. This may be a result of the short duration of action of DOACs compared to VKA,[51-53] with missed DOAC doses potentially leaving patients subtherapeutically anticoagulated for longer periods than missed VKA doses. Our results are the first to demonstrate the magnitude of these effects on major clinical outcomes.

In an apparent paradox, higher adherence to OACs was associated with lower risk of major bleeding. We conducted some exploratory analyses (e.g., examining only GI bleeding, concurrent NSAID, antiplatelet, or gastroprotective drug therapy, further HAS-BLED stratum analyses) to identify potential confounders, but this deserves further study. Residual confounding is possible, for example from patients who are more adherent engaging in more bleeding risk-reducing behaviours compared to less adherent patients (so-called healthy adherer effects),[48, 49] though our falsification endpoint analysis makes this less likely. The possibility that the relationship between OAC adherence and major bleeding behaves differently than efficacy outcomes deserves investigation. Regardless, we found no safety advantage to OAC nonadherence, and our results clearly show that improving OAC adherence does not come at the cost of more major bleeding.

Others have demonstrated that poor OAC adherence is associated with worse clinical outcomes in patients with AF.[11-16] However, these prior studies had several methodological limitations which ours overcomes: We used one of the world's most comprehensive administrative datasets which includes complete medication prescribing records regardless of payer. We avoided prevalent user biases with a new-user and incident cohort design.[54-56] We achieved high statistical power via our large sample size. We used adherence as a continuous variable, revealing the effects of incremental and relatively small (e.g., 10%) changes in adherence, which is not possible when adherence is treated as binary as it is in most studies. We used a rigorous scheme to distinguish between OACs in use at the time of the event which allowed us to compare effect estimates between OACs. Lastly, we included VKA recipients, a group routinely excluded from population-based studies due to difficulties in accurately ascertaining PDC.

Limitations

These results should be interpreted considering the study's limitations. We assumed that filling a prescription equates to consuming the medication, which may not always be true. Some variables

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

known to affect adherence (e.g., education level, adverse effects experienced, psychosocial factors) were absent from the administrative databases, limiting our ability to account for their contributions. Requiring at least two prescription fills for inclusion in the cohort meant that we excluded those who never initiated therapy or stopped after one prescription fill, a potentially high-risk subpopulation. The available data did not include laboratory values, so we were unable to validate VKA adherence with INR values or include measures of renal function in study models. There were too few edoxaban recipients and too few of certain events (ICH, deaths due to bleeding, AF, or stroke) to permit analyses. Finally, our data covered only through the end of 2019, although this coincided with the beginning of the COVID-19 pandemic which resulted in major changes to prescription filling and drug coverage for OACs in British Columbia. Hence, our results are not confounded by those disruptions to the medication supply system and its effects on prescribing and adherence.

CONCLUSIONS

Even small reductions in OAC adherence in patients with AF are associated with significant increases in risk of SSE and death, and these effects are significantly greater with DOAC nonadherence than with VKA nonadherence, These results suggest that DOAC recipients are more vulnerable than VKA recipients to increased risk of stroke and death even with small reductions in adherence. The worsening efficacy outcomes associated with decreasing adherence occur without any benefit in terms of major bleeding reduction.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

KEY POINTS

- Decreased OAC adherence in patients with AF is likely to yield significantly increased risk of stroke and death, particularly among DOAC recipients.
- Even small reductions in OAC adherence are associated with increased risk of stroke and death in AF patients.
- Negative effects of reduced OAC adherence on clinical outcomes are significantly greater with DOACs than VKA, and DOAC recipients are more vulnerable than VKA recipients to increased risk of stroke and death even with small reductions in adherence.
- Lower OAC adherence does not provide a safety advantage in terms of lower risk of major bleeding.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

REFERENCES

1. Lip GY, Brechin CM and Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. *Chest* 2012; 142: 1489-1498. 2012/03/31. DOI: 10.1378/chest.11-2888.
2. Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. *J Geriatr Cardiol* 2017; 14: 195-203. DOI: 10.11909/j.issn.1671-5411.2017.03.011.
3. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. *Stroke* 2005; 36: 1115-1119. 2005/05/10. DOI: 10.1161/01.STR.0000166053.83476.4a.
4. Fang MC, Go AS, Chang Y, et al. Long-term survival after ischemic stroke in patients with atrial fibrillation. *Neurology* 2014; 82: 1033-1037. DOI: 10.1212/WNL.0000000000000248.
5. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *The New England Journal of Medicine,* 2013; 369: 2093-2104. DOI: 10.1056/NEJMoa1310907.
6. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. *The Canadian journal of cardiology* 2012; 28: 125-136. 2012/03/22. DOI: 10.1016/j.cjca.2012.01.021.
7. European Society of Cardiology. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Heart Journal,* 2016; 20. DOI: 10.1093/eurheartj/ehw210.
8. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. *Journal of the American Heart Association,* ; 0: CIR.0000000000000665. DOI: doi:10.1161/CIR.0000000000000665.
9. Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. *BMJ Open* 2020; 10: e034778. 2020/04/11. DOI: 10.1136/bmjopen-2019-034778.
10. Ozaki AF, Choi AS, Le QT, et al. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes* 2020; 13: e005969. 2020/03/10. DOI: 10.1161/circoutcomes.119.005969.
11. Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. *Int J Cardiol,* 2016; 215: 11-13. 2016/04/23. DOI: 10.1016/j.ijcard.2016.03.212.
12. Deshpande CG, Kogut S, Laforge R, et al. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. *Curr Med Res Opin* 2018; 34: 1285-1292. DOI: 10.1080/03007995.2018.1428543.
13. Borne RT, O'Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. *BMC Cardiovascular Disorders,* 2017; 17: 236. 2017/09/04. DOI: 10.1186/s12872-017-0671-6.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

14. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. *American Heart Journal,* 2014; 167: 810-817. 2014/06/04. DOI: 10.1016/j.ahj.2014.03.023.

15. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. *Journal of the American Heart Association*; 5: e003074. DOI: 10.1161/JAHA.115.003074.

16. Alhazami M, Pontinha VM, Patterson JA, et al. Medication Adherence Trajectories: A Systematic Literature Review. *J Manag Care Spec Pharm* 2020; 26: 1138-1152. 2020/08/29. DOI: 10.18553/jmcp.2020.26.9.1138.

17. Gabet A, Chatignoux E, Grave C, et al. Stroke Incidence and Death in Atrial Fibrillation Patients Newly Treated with Direct Oral Anticoagulants. *Clin Epidemiol* 2021; 13: 131-140. 2021/03/02. DOI: 10.2147/clep.S290707.

18. Baumgartner PC, Haynes RB, Hersberger KE, et al. A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. *Frontiers in pharmacology* 2018; 9: 1290-1290. DOI: 10.3389/fphar.2018.01290.

19. Chen A, Stecker E and B AW. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. *J Am Heart Assoc* 2020; 9: e017559. 2020/06/17. DOI: 10.1161/jaha.120.017559.

20. Fawzy AM and Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. *Expert Opinion on Drug Metabolism & Toxicology* 2019; 15: 381-398. DOI: 10.1080/17425255.2019.1604686.

21. Clarkesmith DE, Pattison HM, Khaing PH, et al. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. *The Cochrane database of systematic reviews* 2017; 4: Cd008600. 2017/04/06. DOI: 10.1002/14651858.CD008600.pub3.

22. British Columbia Ministry of Health. About Population Data BC, https://www.popdata.bc.ca/ (2021).

23. British Columbia Ministry of Health [creator] (2019). Medical Services Plan (MSP) Payment Information File. V2. Population Data BC [publisher]. Data Extract. MOH (2020). http://www.popdata.bc.ca/data.

24. Canadian Institute for Health Information [creator] (2019). Discharge Abstract Database (Hospital Separations). V2. Population Data BC [publisher]. Data Extract. MOH(2020). http://www.popdata.bc.ca/data.

25. British Columbia Ministry of Health [creator] (2020). Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC [publisher]. Data Extract. MOH(2020). http://www.popdata.bc.ca/data.

26. British Columbia Ministry of Health [creator] (2020). Vital Events Deaths. V2. Population Data BC [publisher]. Data Extract. MOH(2020). http://www.popdata.bc.ca/data.

27. British Columbia Ministry of Health [creator] (2020). PharmaNet. V2. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee(2020). http://www.popdata.bc.ca/data.

28. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; 61: 344-349. 2008/03/04. DOI: 10.1016/j.jclinepi.2007.11.008.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

29. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015; 12: e1001885. 2015/10/07. DOI: 10.1371/journal.pmed.1001885.

30. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *Bmj* 2018; 363: k3532. 2018/11/16. DOI: 10.1136/bmj.k3532.

31. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. *Am Heart J* 2015; 169: 39-44 e32. DOI: 10.1016/j.ahj.2014.09.014.

32. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. *American heart journal* 2015; 169: 39-44 e32. DOI: 10.1016/j.ahj.2014.09.014.

33. Centers for Disease Control and Prevention Division for Heart Disease and Stroke Prevention. Calculating proportion of days covered (PDC) for antihypertensive and antidiabetic medications: an ebaluation guide for grantees. . In: (NCCDPHP) NCfCDPaHP, (ed.). USA2015.

34. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. *Value Health* 2009; 12: 989-995. 2009/05/01. DOI: 10.1111/j.1524-4733.2009.00543.x.

35. Karve S, Cleves MA, Helm M, et al. An Empirical Basis for Standardizing Adherence Measures Derived from Administrative Claims Data among Diabetic Patients. *Medical care* 2008; 46: 1125-1133.

36. Hernandez I, He M, Chen N, et al. Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. *J Am Heart Assoc* 2019; 8: e011427. 2019/06/14. DOI: 10.1161/jaha.118.011427.

37. Salmasi S, Höegg T, Safari A, et al. SM1 The Random Effects Warfarin Days' Supply (REWARDS) Model: Development and Validation of a NOVEL Method to Estimate Exposure to Warfarin Using Administrative Data. *Value in Health* 2021; 24: S241. DOI: 10.1016/j.jval.2021.04.1210.

38. Sandhu RK, Wilton SB, Cruz J, et al. An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. *CJC Open* 2019; 1: 198-205. 2020/03/12. DOI: 10.1016/j.cjco.2019.05.007.

39. Cox JL, Dai S, Gong Y, et al. The Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation. *Can J Cardiol* 2016; 32: 1566-1569. 2016/06/15. DOI: 10.1016/j.cjca.2016.02.059.

40. Leong M, Stang JM, McGuire N, et al. Regional Variation in Transient Ischemic Attack and Minor Stroke in Alberta Emergency Departments. *Stroke* 2020; 51: 1820-1824. DOI: doi:10.1161/STROKEAHA.119.027960.

41. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010; 137: 263-272. 2009/09/19. DOI: 10.1378/chest.09-1584.

42. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. *J Am Coll Cardiol* 2011; 57: 173-180. 2010/11/30. DOI: 10.1016/j.jacc.2010.09.024.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

43. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; 138: 1093-1100. 2010/03/20. DOI: 10.1378/chest.10-0134.
44. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005; 43: 1130-1139. 2005/10/15. DOI: 10.1097/01.mlr.0000182534.19832.83.
45. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017; 17: 230. 2017/10/12. DOI: 10.1186/s12877-017-0621-2.
46. Stauffer ME, Hutson P, Kaufman AS, et al. The Adherence Rate Threshold is Drug Specific. *Drugs R D* 2017; 17: 645-653. DOI: 10.1007/s40268-017-0216-6.
47. Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. *Ther Clin Risk Manag* 2015; 11: 967-977. 2015/07/08. DOI: 10.2147/tcrm.S84210.
48. Ladova K, Vlcek J, Vytrisalova M, et al. Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. *J Eval Clin Pract* 2014; 20: 111-116. 2013/11/06. DOI: 10.1111/jep.12095.
49. Shrank WH, Patrick AR and Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. *J Gen Intern Med* 2011; 26: 546-550. 2011/01/05. DOI: 10.1007/s11606-010-1609-1.
50. Bijlsma MJ, Vansteelandt S, Janssen F, et al. The effect of adherence to statin therapy on cardiovascular mortality: quantification of unmeasured bias using falsification end-points. *BMC Public Health* 2016; 16: 303. 2016/04/14. DOI: 10.1186/s12889-016-2986-0.
51. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; 383: 955-962. 2013/12/10. DOI: 10.1016/s0140-6736(13)62343-0.
52. Stangier J and Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. *Clin Appl Thromb Hemost* 2009; 15 Suppl 1: 9s-16s. 2009/08/22. DOI: 10.1177/1076029609343004.
53. Fawzy AM and Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. *Expert Opin Drug Metab Toxicol* 2019; 15: 381-398. 2019/04/06. DOI: 10.1080/17425255.2019.1604686.
54. Lund JL, Richardson DB and Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol Rep* 2015; 2: 221-228. 2016/03/10. DOI: 10.1007/s40471-015-0053-5.
55. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol* 2003; 158: 915-920. 2003/10/31. DOI: 10.1093/aje/kwg231.
56. Luijken K, Spekreijse JJ, van Smeden M, et al. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices. *Pharmacoepidemiol Drug Saf* 2021; 30: 960-974. 2021/04/27. DOI: 10.1002/pds.5258.
57. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm* 2019; 16: e66-e93. 2019/02/01. DOI: 10.1016/j.hrthm.2019.01.024.

58. Lip GY and Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *Jama* 2015; 313: 1950-1962. 2015/05/20. DOI: 10.1001/jama.2015.4369.

59. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012; 33: 2719-2747. 2012/08/28. DOI: 10.1093/eurheartj/ehs253.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

TABLES & FIGURES

Table 1: Characteristics of study patients at index date

Patient Characteristic	Overall (n = 34,946)	Males (n = 19,379)	Females (n = 15,567)
Female	15567 (44.5%)		
Age, mean (SD)	70.1 y ± 11.3	67.9 (11.5)	72.9 (10.3)
Age category			
<55	3183 (9.1%)	2445 (7.0%)	738 (2.1)
55-65	6983 (20.0%)	4553 (13.0%)	2430 (7.0%)
65-75	11413 (32.7%)	6400 (18.3%)	5013 (14.3%)
≥75	13367 (38.3%)	5981 (17.1%)	7386 (21.1%)
Neighborhood income quintile [d]	3.0 ± 1.4	3.0 ± 1.4	2.8 ± 1.4
Socioeconomic status category			
<2	7335 (21.0%)	3722 (10.7%)	3620 (10.4%)
2-3	7132 (20.4%)	3752 (10.7%)	3393 (9.7%)
3-4	6862 (19.6%)	3873 (11.1%)	2966 (8.5%)
≥4	13617 (39.0%)	8032 (23.0%)	5588 (16.0%)
Index OAC			
Warfarin	24927 (71.3%)	13825 (39.6%)	11102 (31.8%)
Dabigatran	2601 (7.4%)	1458 (4.2%)	1143 (3.3%)
Rivaroxaban	4714 (13.5%)	2622 (7.5%)	2092 (6.0%)
Apixaban	2693 (7.7%)	1469 (4.2%)	1224 (3.5%)
Edoxaban	11 (0.0%)	5 (0.0%)	6 (0.0%)
Characteristics measured during baseline period (1 year prior to index date)			
CHA_2DS_2-VASc score, median (IQR) [e]	3 (2, 4)	2 (1, 4)	3 (2, 4)
HAS-BLED score, median (IQR) [f]	2 (1, 3)	2 (1, 3)	2 (2, 3)
Weighted Charlson Comorbidity Index, median (IQR) [g]	5 (3, 8)	5 (3, 8)	5 (3, 8)
Hypertension	17546 (50.2%)	10636 (30.4%)	10108 (28.9%)
Vascular disease	9723 (27.8%)	5765 (16.5%)	3958 (11.3%)
Diabetes	6655 (19.0%)	3992 (11.4%)	2663 (7.6%)
Congestive heart failure	5461 (15.6%)	2951 (8.4%)	2510 (7.2%)

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Stroke/TIA	3427 (9.8%)	1692 (4.8%)	1735 (5.0)
Abnormal renal function	2248 (6.4%)	1162 (3.3%)	1086 (3.1%)
Major bleeding	2778 (7.9%)	1664 (4.8%)	1114 (3.2%)
Abnormal liver function	353 (1.0%)	210 (0.6%)	143 (0.4%)
Alcohol use	213 (0.6%)	170 (0.5%)	43 (0.1%)
Prescribed nonsteroidal anti-inflammatory (NSAID) or antiplatelet drug, median (IQR) [h]	0 (0-1)	0 (0-1)	0 (0-1)

OAC: Oral Anticoagulants. TIA: Transient ischemic attack. IQR: Interquartile range.

Values are n (%), mean ± standard deviation, median (IQR), unless otherwise stated.

[d] Neighborhood income quintile represents the average equivalized disposable income by postal code in patients' residential area at index date, with 1 as the lowest and 5 as the highest level.

[e] Stroke risk score calculated based on the presence of comorbidities: Cardiomyopathy (1 point), Hypertension (1 point), Age≥75 (2 points), Diabetes (1 point), Stroke (2 points), Vascular disease (1 point), Age 65–75 (1 point), Sex category female (1 point). Scored if at least one disease specific ICD code was present in either outpatient or inpatient records during the baseline period. Ascertainment scheme is in Supplemental appendix Table A1.

[f] Bleeding risk score calculated based on the presence of comorbidities: Hypertension (1 point), Abnormal liver/kidney function (1 point), Stroke (1 point), Bleeding (1 point), Age > 75 years (1 point), Drugs (NSAID or antiplatelet) or alcohol use (1 point). Scored if at least one disease specific ICD code was present in either outpatient or inpatient records during the baseline period. Ascertainment scheme is in Supplemental appendix Tables A1 and A2.

[g] Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. Possible range of scores: 0-31. Zero indicates that no comorbidities were found. Ascertainment scheme is in Supplemental appendix Table A1.

[h] NSAIDs and ASA could be obtained with or without a prescription in the study jurisdiction.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2: Study outcomes

Outcome model	Frequency	Median time to event in years (IQR)
Primary outcomes		
SSE, TIA, or death*	13,543	5.6 (2.8-9.5)
SSE*	1804	4.3 (1.8-7.7)
Secondary outcomes		
SSE or TIA*	2377	4.2 (1.7-7.6)
Ischemic stroke*	1467	4.2 (1.8-7.6)
Death (any cause)	13,096	6.1 (3.2-10)
Cardiovascular death	5306	6.3 (3.3-10.2)
Major bleeding**	3839	3.7 (1.5-7.1)
Nontraumatic intracranial hemorrhage	300	4.2 (1.8-7.3)

SSE: stroke or systemic embolism. Ascertainment scheme in Supplemental appendix.
TIA: transient ischemic attack. Ascertainment scheme in Supplemental appendix.
*after excluding patients with SSE within the previous 5 years
**after excluding patients with major bleeding within the previous 5 years
Study outcome definitions are in Supplemental appendix Table A3.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

604 **Table 3: Effects of OAC adherence on clinical outcomes by OAC class**

Outcome	Number of events	Drug	HR (95% CI)*	Change in hazard of outcome per 10% absolute decrease in PDC (95%CI)	Contrast test for DOAC vs. VKA HR (95%CI); p-value	Detailed model outputs
SSE, TIA, or death (co-primary outcome)	13,543	any OAC	0.992 (0.987 – 0.997)	0.8% (0.3-1.3) increase		Supplemental appendix A 6.1
		VKA	0.959 (0.947 – 0.972)	4.3% (2.9-5.6) increase	0.946 (0.919-0.973); p<0.001	Supplemental appendix A 6.3
		DOAC	0.907 (0.885 – 0.930)	10.3% (7.5-13.0) increase		
SSE (co-primary outcome)	1804	any OAC	0.901 (0.887 – 0.914)	11% (9.4-12.7) increase		Supplemental appendix A 6.2
		VKA	0.816 (0.797 – 0.836)	22.5% (19.6-25.4) increase	0.913 (0.866-0.961); p<0.001	Supplemental appendix A 6.4
		DOAC	0.745 (0.711 – 0.780)	34.2% (28.2-40.6) increase		
SSE or TIA	2377	VKA	0.824 (0.807 – 0.840)	21.4% (19.0-23.9) increase	0.926 (0.885-0.968); p<0.001	Supplemental appendix A 6.5
		DOAC	0.762 (0.732 – 0.794)	31.2% (25.9-36.6) increase		
Ischemic stroke	1467	VKA	0.802 (0.780 – 0.824)	24.7% (21.4-28.2) increase	0.930 (95%CI 0.877-0.986); p=0.014	Supplemental appendix A 6.6
		DOAC	0.745 (0.708 – 0.785)	34.2% (27.4-41.2) increase		
All-cause death	13,096	VKA	1.005 (0.986	NS	0.941	Supplemental

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

			– 1.024)		(0.907-0.977); p<0.001	appendix A 6.7
		DOAC	0.946 (0.916 – 0.977)	5.7% increase		
Cardiovascular death	5306	VKA	0.999 (0.971 – 1.028)	NS	0.919 (95%CI 0.869-0.971); p=0.003	Supplemental appendix A 6.8
		DOAC	0.918 (0.875 – 0.963)	8.9% (3.8-14.3) increase		
Major bleeding	3839	VKA	0.850 (0.839 – 0.862)	17.6% (16.0-19.2) increase	1.019 (0.982-1.058); p=0.317	Supplemental appendix A 6.9
		DOAC	0.863 (0.834 – 0.893)	15.9% (9.3-19.9) increase		

*HRs are relative hazard per 10% increase in PDC.

NS: not statistically significant; SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist; DOAC: direct-acting oral anticoagulant; PDC: proportion of days covered

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

610 **Figure 1: Study design**



611

612

613

614

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 2: Increase in hazard of clinical event per 10% reduction in PDC by OAC drug class



*VKA vs. DOAC test for contrast p<0.001
**VKA vs. DOAC test for contrast p=0.85
SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist; DOAC: direct-acting oral anticoagulant; PDC: proportion of days covered

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 3: Change in log relative hazard of primary outcomes vs. PDC by OAC class



SSE: stroke or systemic embolism; TIA: transient ischemic attack; VKA: vitamin K antagonist; DOAC: direct-acting oral anticoagulant; PDC: proportion of days covered

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4: Increase in hazard of clinical event per 10% reduction in PDC by OAC drug



* test for contrast

medRxiv preprint doi: https://doi.org/10.1101/2023.07.18.23292847; this version posted July 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

634